Skip to main content

Table 2 Resource costs parameters used in Markov model (THB as of 2009 value)

From: Is a HIV vaccine a viable option and at what price? An economic evaluation of adding HIV vaccination into existing prevention programs in Thailand

Parameters

Distribution

Mean

SE

References

Costs of prevention program

    

Annual costs of existing prevention programs

Gamma

24

 

[27, 28]

Cost of HIV vaccine per course

Gamma

3,500

 

[12]

Individual cost of community engagement

Gamma

937*

  

Cost of HIV screening (ELISA) for vaccine acceptance

Gamma

125

 

[47]

Cost of pre-counselling for all vaccinations

Gamma

141

 

[47]

Cost of post-counselling for vaccine acceptance

Gamma

58

 

[47]

Costs of treatment program

    

Costs of asymptomatic treatment

    

Laboratory cost for asymptomatic patient

Gamma

8,155

 

[29]

Hospital service cost of asymptomatic patient

Gamma

2,502

 

[29]

OPD cost of asymptomatic patient

Gamma

2,502

 

[29]

Costs of symptomatic treatment

    

Lab test cost for symptomatic patient

Gamma

8,931

 

[29]

Opportunity infection treatment cost of symptomatic patient

Gamma

4,739

 

[29]

Hospital service cost of symptomatic patient

Gamma

9,104

 

[29]

OPD cost of symptomatic patient

Gamma

2,502

 

[29]

IPD cost of symptomatic patient

Gamma

6,227

 

[29]

Costs of AIDS treatment

    

Opportunity infection treatment cost of AIDS patient

Gamma

4,739

 

[29]

Hospital service cost of AIDS patient

Gamma

9,104

 

[29]

OPD cost of AIDS patient

Gamma

2,502

 

[29]

IPD cost of AIDS patient

Gamma

6,227

 

[29]

Annual drug costs of the first-line ART regimens (mg):

Gamma

8,184†

1,858†

 

1. d4T(30)+3TC(150)+NVP(200) or

    

2. d4T(30) + 3TC(150) + EFV (600) or

    

3. AZT(100/200/250/300)+3TC(150)+NVP(200) or

    

4. AZT(100/200/300)+3TC(150)+EFV(600)

    

Annual drug costs of the second-line ART regimens (mg):

Gamma

32,478†

5,772†

 

1. ddI(250)+3TC(150)+NVP(200) or

    

2. ddI(250)+3TC(150)+EFV(600) or

    

3. TDF(300)+3TC(150)+NVP(200) or

    

4. TDF(300)+3TC(150/300)+EFV(600)

    

Annual drug costs of the third-line ART regimens (mg):

Gamma

15,682†

2,080†

 

1. AZT(100/200/300)+3TC(150)+Boosted PIs‡ or

    

2. d4T(30)+3TC(150)+Boosted PIs‡ or

    

3. TDF(300)+3TC(150)+Boosted PIs‡ or

    

4. ddI(250)+3TC(150)+Boosted PIs‡ or

    

5. AZT(100/200/300)+ddI(250)+Boosted PIs‡ or

    

6. AZT(100/200/300)+TDF(300)+Boosted PIs‡ or

    

7. AZT(100/200/300)+3TC(150)+TDF(300)+Boosted PIs‡

    

Annual costs of lab test of first-line ART regimen in the first year

Gamma

7,671

 

[48]

Annual costs of lab test of first-line ART regimen in subsequence years

Gamma

4,210

 

[48]

Annual costs of lab test of the second-line ART regimen

Gamma

4,140

 

[48]

Annual costs of lab test of the third-line ART regimen

Gamma

4,163

 

[48]

  1. SE: standard error; THB: Thai baht; OPD: outpatient department; IPD: inpatient department; ART: antiretroviral treatment; d4T: stavudine; 3TC: lamivudine; NVP: nevirapine; EFV: efavarenze; AZT; zidovudine; TDF: tenofovir; ddI: dianosine; and PIs: protease inhibitors.
  2. *Nakorn Premsri, National Vaccine Committee Office, Department of Disease Control, Ministry of Public Health, personal communication, August 25, 2009.
  3. †Thanapat Laowahutanon, AIDS office, Bureau of Disease Management, National Health Security Office, personal communication, August 20, 2009.
  4. ‡Boosted PIs were recommended by National Health Security Office as follows: the first-line PIs regimen, LPV/r-- lopinavir (200 mg) + ritonavir(50 mg) or IDV/r-- indinavir (400 mg) + ritonavir (100 mg) and the second-line PIs regimen, ATV/r-- atazanavir (150 mg)+ ritonavir (100 mg)